Stocksigma LogoStocksigma Logo

Emcure Pharmaceuticals Board Approves Merger of Wholly Owned Subsidiaries Zuventus and Emcutix

Emcure Pharmaceuticals' board approved a draft Composite Scheme of Amalgamation on 12th Oct'26 to merge its wholly owned subsidiaries, Zuventus Healthcare

Emcure Pharmaceuticals Board Approves Merger of Wholly Owned Subsidiaries Zuventus and Emcutix

Emcure Pharmaceuticals Ltd 路 Others (Uncategorized) 路 12 Oct 2026, 3:59 pm

Emcure Pharmaceuticals Board Approves Merger of Wholly Owned Subsidiaries Zuventus and Emcutix Emcure Pharmaceuticals' board approved a draft Composite Scheme of Amalgamation on 12th Oct'26 to merge its wholly owned subsidiaries, Zuventus Healthcare and Emcutix Biopharmaceuticals, into itself. For FY25-26, Zuventus reported revenue of INR 1,040.58 crore (net worth INR 871.46 crore), Emcutix posted revenue of INR 29.37 crore (net worth INR -13.07 crore), and Emcure generated revenue of INR 5,243.19 crore. Designed to drive operational efficiencies and rationalization, the merger involves no cash outlay or new share issuance, leaving Emcure's shareholding unchanged, subject to NCLT Mumbai approval.

Original exchange filing (PDF)

More announcements from Emcure Pharmaceuticals Ltd

All Emcure Pharmaceuticals Ltd announcements